Long-term treatment of patients with HIV-1: the role of atazanavir

Miguel &Aacute;ngel Artacho1, Pablo Barreiro2, Jos&eacute; Vicente Fern&aacute;ndez-Montero21Department of Internal Medicine, Hospital Universitario Gregorio Mara&ntilde;&oacute;n, Madrid, Spain; 2Department of Infectious Diseases, Hospital Carlos III, Madrid,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Miguel &Aacute;ngel Artacho, Pablo Barreiro, Jos&eacute; Vicente Fern&aacute;ndez-Montero
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/ba8bf49fa7414d46bf6e61e2e48d3546
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ba8bf49fa7414d46bf6e61e2e48d3546
record_format	dspace
spelling	oai:doaj.org-article:ba8bf49fa7414d46bf6e61e2e48d35462021-12-02T04:50:39ZLong-term treatment of patients with HIV-1: the role of atazanavir1179-1373https://doaj.org/article/ba8bf49fa7414d46bf6e61e2e48d35462010-09-01T00:00:00Zhttp://www.dovepress.com/long-term-treatment-of-patients-with-hiv-1-the-role-of-atazanavir-a5267https://doaj.org/toc/1179-1373Miguel &Aacute;ngel Artacho1, Pablo Barreiro2, Jos&eacute; Vicente Fern&aacute;ndez-Montero21Department of Internal Medicine, Hospital Universitario Gregorio Mara&ntilde;&oacute;n, Madrid, Spain; 2Department of Infectious Diseases, Hospital Carlos III, Madrid, SpainBackground: The introduction of highly-active antiretroviral therapy (HAART) remains a major milestone in the management of HIV-infected patients. Protease inhibitors (PI) are commonly used as part of triple combinations, given that to antiviral potency, better tolerance and convenience has been achieved in recent years.Objective: To summarize and update evidence-based information about atazanavir (ATV) on initial, simplification, and rescue interventions in HIV patients.Methods: Review of observational and randomized trials reported in medical conferences, peer-reviewed journals, and treatment guidelines.Results: ATV is a second-generation PI, which has shown across studies potent antiviral activity and high genetic barrier, both in HAART-na&iuml;ve patients or after virological failure. Indulgent metabolic profile, in terms of insulin glucose and lipid levels, adds value to this drug for the long-term management of HIV infection.Keywords: atazanavir, HAART, protease inhibitors Miguel &Aacute;ngel ArtachoPablo BarreiroJos&eacute; Vicente Fern&aacute;ndez-MonteroDove Medical PressarticleImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol 2010, Iss default, Pp 157-166 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607
spellingShingle	Immunologic diseases. Allergy RC581-607 Miguel &Aacute;ngel Artacho Pablo Barreiro Jos&eacute; Vicente Fern&aacute;ndez-Montero Long-term treatment of patients with HIV-1: the role of atazanavir
description	Miguel &Aacute;ngel Artacho1, Pablo Barreiro2, Jos&eacute; Vicente Fern&aacute;ndez-Montero21Department of Internal Medicine, Hospital Universitario Gregorio Mara&ntilde;&oacute;n, Madrid, Spain; 2Department of Infectious Diseases, Hospital Carlos III, Madrid, SpainBackground: The introduction of highly-active antiretroviral therapy (HAART) remains a major milestone in the management of HIV-infected patients. Protease inhibitors (PI) are commonly used as part of triple combinations, given that to antiviral potency, better tolerance and convenience has been achieved in recent years.Objective: To summarize and update evidence-based information about atazanavir (ATV) on initial, simplification, and rescue interventions in HIV patients.Methods: Review of observational and randomized trials reported in medical conferences, peer-reviewed journals, and treatment guidelines.Results: ATV is a second-generation PI, which has shown across studies potent antiviral activity and high genetic barrier, both in HAART-na&iuml;ve patients or after virological failure. Indulgent metabolic profile, in terms of insulin glucose and lipid levels, adds value to this drug for the long-term management of HIV infection.Keywords: atazanavir, HAART, protease inhibitors
format	article
author	Miguel &Aacute;ngel Artacho Pablo Barreiro Jos&eacute; Vicente Fern&aacute;ndez-Montero
author_facet	Miguel &Aacute;ngel Artacho Pablo Barreiro Jos&eacute; Vicente Fern&aacute;ndez-Montero
author_sort	Miguel &Aacute;ngel Artacho
title	Long-term treatment of patients with HIV-1: the role of atazanavir
title_short	Long-term treatment of patients with HIV-1: the role of atazanavir
title_full	Long-term treatment of patients with HIV-1: the role of atazanavir
title_fullStr	Long-term treatment of patients with HIV-1: the role of atazanavir
title_full_unstemmed	Long-term treatment of patients with HIV-1: the role of atazanavir
title_sort	long-term treatment of patients with hiv-1: the role of atazanavir
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/ba8bf49fa7414d46bf6e61e2e48d3546
work_keys_str_mv	AT miguelampaacutengelartacho longtermtreatmentofpatientswithhiv1theroleofatazanavir AT pablobarreiro longtermtreatmentofpatientswithhiv1theroleofatazanavir AT josampeacutevicentefernampaacutendezmontero longtermtreatmentofpatientswithhiv1theroleofatazanavir
_version_	1718401032156872704

Long-term treatment of patients with HIV-1: the role of atazanavir

Ejemplares similares